drug_name,company,summary,classification,path_to_future_approval,link
vusolimogene oderparepvec,"Replimune, Inc.","The application provides data from RPL-001-16, a single-arm Phase 2 trial of vusolimogene oderparepvec in combination with nivolumab. The numerically higher response rate cannot be adequately interpreted due to heterogeneity of the patient population and the trial was not designed to isolate the contribution of vusolimogene oderparepvec to the observed ORR. Therefore, the RPL-001-16 trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.",efficacy,Conduct and provide results from adequate and well-controlled clinical trial(s) which demonstrate substantial evidence of effectiveness. Submit a revised study protocol that assesses the individual contribution of vusolimogene oderparepvec to the observed ORR and provide a detailed justification for the statistical assumptions that support primary efficacy endpoints.,https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA125827_20250721.pdf
odronextamab,"Regeneron Pharmaceuticals, Inc.","The Agency has determined that a confirmatory trial is required to be underway for odronextamab for large B-cell lymphoma (LBCL) prior to approval. However, a confirmatory trial in LBCL with odronextamab is not considered to be underway. The current conduct of OLYMPIA-3 and projected completion date do not provide sufficient assurance of timely completion of the trial. The application also requires a safety update.",efficacy,"The Agency has determined that a confirmatory trial is required to be underway for odronextamab for large B-cell lymphoma (LBCL) prior to approval. To support resubmission of the BLA, you must address this deficiency. After enrollment and analysis of Part 1 (dose-finding) is completed, we recommend that you request a meeting with the Agency to discuss trial benchmarks (e.g., enrollment goals, site activation, proportion of primary endpoint events accrued, trial completion date) to allow measurement of the progress of the trial. You should demonstrate in your submission that your milestones are appropriate and that, prior to approval, you will demonstrate sufficient progress in the conduct of the confirmatory portion of the confirmatory trial to provide sufficient assurance of timely completion of the trial. Additionally, a safety update is required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761303Original2_20240322.pdf
tabelecleuce,"Atara Biotherapeutics, Inc.","The FDA cannot grant final approval due to deficiencies in Chemistry, Manufacturing, and Controls, specifically unresolved inspectional observations regarding the manufacturing facility and compliance with current good manufacturing practice requirements. Labeling comments are reserved until the application is otherwise acceptable.",manufacturing,"Corrections to FDA's inspectional observations issued to the facility located in (b) (4) have not been adequately demonstrated, may require additional review during a follow-up inspection, and, therefore, remain unresolved. At this time, CBER cannot determine pursuant to 21 CFR 601.20(a) and (d) that the product and establishment listed in the BLA comply with the standards established in the BLA and the requirements prescribed in FDA regulations, including current good manufacturing practice requirements. The sponsor must also address labeling concerns.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA125745_20250115.pdf
HER3-DXd,"Daiichi Sankyo, Inc.","The FDA issued a Complete Response Letter for HER3-DXd due to deficiencies found during facility inspections, issues with prescribing information and labeling, and the confirmatory study not meeting its pre-specified efficacy boundary for PFS.",multiple,"The facility must provide satisfactory responses to deficiencies noted during the pre-license inspection. The sponsor must also address deficiencies related to prescribing information, carton and container labeling, medication guide, and proprietary name. A safety update with new safety data from clinical trials is required. Additionally, the proposed confirmatory study did not meet the pre-specified efficacy boundary for PFS at the interim analysis, and the sponsor is recommended to request a post-action meeting to discuss alternative trials to verify clinical benefit.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761366_20240626.pdf
INTP5,Accord BioPharma Inc.,"The FDA cannot approve the application in its present form due to deficiencies identified during facility inspections, product quality (microbiology) issues, and the need for a safety update with additional data and analysis.",multiple,"The sponsor must address deficiencies from facility inspections, including resolving related deficiencies and potentially undergoing re-inspection. They also need to provide a comprehensive safety update with new clinical data, detailed analysis of adverse events, and updated exposure information. Additionally, they must resubmit the proposed proprietary name.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761147_20240405.pdf
PB2452,"SFJ Pharmaceuticals, Inc.","The FDA issued a Complete Response Letter for PB2452 due to deficiencies in product quality, quality microbiology, facility inspections, and safety updates. The application cannot be approved in its present form.",multiple,"The sponsor must address deficiencies related to product quality, quality microbiology, facility inspections, and safety updates. This includes providing satisfactory responses to FDA 483 deficiencies, submitting new safety data from clinical studies/trials, and updating safety profiles. A complete response addressing all deficiencies is required for resubmission.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761290_20250131.pdf
AEB1102,Immedica Pharma AB,"The application for AEB1102 was not approved due to deficiencies in establishing efficacy, safety concerns related to dose adjustment and monitoring, and lack of data for pediatric patients. The submitted data did not adequately support plasma arginine as a validated surrogate endpoint predictive of clinical benefit.",multiple,"The sponsor needs to conduct a trial that assesses clinical outcomes to validate that plasma arginine and/or its metabolites are predictive of clinical benefit. They also need to address dose adjustment and monitoring requirements for safe and effective use, provide additional safety data, especially for pediatric patients (less than 2 years of age), and characterize the adequacy of AEB1102 dosing for subcutaneous initiation without prior intravenous treatment.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761211_20250806.pdf
deramiocel,"Capricor, Inc.","The application provides data from the HOPE-2 and HOPE-2-OLE studies as primary and supportive evidence of effectiveness, respectively. The HOPE-2 study failed to demonstrate efficacy for its prespecified primary and secondary endpoints. Post hoc analyses were not sufficient to provide substantial evidence of effectiveness to support approval. The HOPE-2 study was not an adequate and well-controlled study with a clear statement of objectives and sufficient prespecified collection of essential baseline clinical data. The submitted data includes numerous secondary and exploratory endpoints that were not prespecified for hypothesis testing, and no prespecified multiplicity adjustment strategy was employed, making these analyses exploratory and not evidence of effectiveness. The BLA does not meet the statutory requirement for substantial evidence of effectiveness.",efficacy,"Conduct adequate and well-controlled study(ies) whose primary objective is evaluation of cardiac outcomes in deramiocel-treated patients with DMD cardiomyopathy, compared to a randomized, concurrent control group over an appropriate duration of follow up.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA125842_20250709.pdf
odronextamab,"Regeneron Pharmaceuticals, Inc.","The application cannot be approved in its present form due to deficiencies identified during facility inspections (CGMP issues), issues with prescribing information and labeling (format, content, and proprietary name), and the need for a comprehensive safety update including new clinical data and adverse event analysis.",multiple,"The sponsor must address deficiencies related to facility inspections (CGMP compliance, potential re-inspection, and pre-license inspection), submit updated prescribing information (labeling format, content, and compliance with regulations), update carton and container labeling, resubmit the proprietary name, and provide a comprehensive safety update including new safety data, adverse event analysis, and updated exposure information. A complete response addressing all deficiencies is required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761303_20250730.pdf
,"Accord BioPharma, Inc.","The FDA cannot approve the application in its present form due to unresolved deficiencies from facility inspections related to drug substance and drug product manufacturing, and outstanding issues regarding safety data updates and presentation. The proposed labeling comments are reserved until the application is otherwise adequate, and the proprietary name is conditionally acceptable pending approval of the application.",multiple,"The company must provide satisfactory responses to deficiencies found during facility inspections, including the date(s) of the facility's response to FDA Form 483. They must also provide a safety update including data from all nonclinical and clinical studies, describe significant changes in the safety profile, incorporate new safety data into sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, provide case report forms and narrative summaries for subjects who died or discontinued due to adverse events, describe information suggesting substantial changes in adverse event incidence, provide updated exposure information, and summarize worldwide safety experience. A resubmission must fully address all listed deficiencies and be clearly marked as ""RESUBMISSION"".",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761147_20250805.pdf
camrelizumab,"Jiangsu Hengrui Pharmaceuticals Co., Ltd","The FDA cannot approve the application in its present form due to deficiencies identified during facility inspections and issues related to prescribing information, carton and container labeling, medication guide, proprietary name, and safety update requirements.",multiple,"The facility must provide satisfactory responses to the deficiencies conveyed by the FDA, including the date(s) of the facility's response to the FDA Form 483. The sponsor must also address all deficiencies related to prescribing information, carton and container labeling, medication guide, proprietary name, and provide a comprehensive safety update as described in the letter. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761308_20250320.pdf
LUBT004,"Lupin Limited (Biotech Division) c/o Lupin Pharmaceuticals, Inc.","The application cannot be approved in its present form due to deficiencies identified during facility inspections, issues with prescribing information and proprietary name, and the need for a comprehensive safety update.",multiple,"The applicant must address all deficiencies listed in the letter, including resolving facility inspection deficiencies, resubmitting the proposed proprietary name, and providing a comprehensive safety update with all nonclinical and clinical study data. A resubmission must be clearly marked as 'RESUBMISSION' and state that it is a complete response to the deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761212_20241114.pdf
XSB-001,Xbrane Biopharma AB,"The application cannot be approved in its present form due to product quality issues, facility inspection deficiencies, and issues with prescribing information, carton/container labeling, and proprietary name.",multiple,"The applicant must address product quality issues, provide satisfactory responses to facility inspection deficiencies, resubmit draft labeling that is responsive to electronic communication and conforms to regulations, resubmit draft carton and container labeling based on proposed revisions, and resubmit the proposed proprietary name after addressing all deficiencies. A safety update including data from all nonclinical and clinical studies is also required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761187_20240419.pdf
Gan & Lee insulin lispro,Gan & Lee Pharmaceuticals,"The application cannot be approved in its present form due to deficiencies related to product quality, facility inspections, and safety updates. Specific issues include lack of acceptance criteria for most tests, unresolved inspection deficiencies at the manufacturing facility, and incomplete safety data.",multiple,"The sponsor must address deficiencies in product quality, resolve inspection deficiencies at the manufacturing facility, and provide a comprehensive safety update including new clinical and nonclinical data, re-tabulated adverse events, and case report forms for serious adverse events and deaths. A resubmission must fully address all deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761357_20240326.pdf
marnetegragene autotemcel,"Rocket Pharmaceuticals, Inc.","The FDA issued a Complete Response Letter for the Biologics License Application due to deficiencies in Chemistry, Manufacturing, and Controls (CMC). The BLA contained numerous revisions and corrections that were confirmed in responses to information requests but were not formally updated in the BLA documents. These include typographical errors in method SOPs, and data/calculation errors in validation reports. Additionally, changes to SSC, AC, or validated assay ranges agreed upon during the review cycle were not appropriately corrected within the BLA submission.",manufacturing,"The sponsor must appropriately correct all changes to SSC, AC, or validated assay ranges within the BLA submission. Revisions to documents or data must be adequately documented with red-lined versions included. All updated, corrected, or revised information discussed during the review cycle must be submitted. A tabulated summary of all changes made, including affected documents, nature of updated information, information request and amendment numbers, and any other pertinent information, must be provided to facilitate review. The sponsor must resubmit the application within one year, fully addressing all listed deficiencies. A meeting or teleconference can be requested to discuss the necessary steps for approval.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA125806_20240614.pdf
INTP5,Accord BioPharma Inc.,"The FDA issued a Complete Response Letter for the biologics license application (BLA) for INTP5 due to unresolved deficiencies identified during multiple pre-license facility inspections. The responses from the facility provided insufficient evidence to confirm that the previously observed deficiencies have been resolved. Additionally, the letter reserves comment on proposed labeling and requires a safety update.",manufacturing,"To gain future approval, the facility must provide satisfactory responses to the deficiencies identified during the FDA inspections. The complete response should include the date(s) of the facility's response(s) to the FDA Form 483, providing documentary evidence that all deficiencies are resolved. The FDA will then evaluate the application's approvability and the resolution of inspection deficiencies, which may include a re-inspection of the facility. The sponsor must also include a safety update with detailed changes or findings in the safety profile, new safety data from clinical studies, and updated exposure information. They also need to provide a summary of worldwide experience on the product's safety and English translations of current approved foreign labeling not previously submitted. The sponsor is encouraged to review labeling resources and resubmit the proposed proprietary name once all deficiencies are addressed.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761147_20241029.pdf
Gan & Lee insulin aspart,Gan & Lee Pharmaceuticals,"The application cannot be approved in its present form due to product quality issues, facility inspection deficiencies, and issues with prescribing information, carton and container labeling, proprietary name, and safety update requirements.",multiple,"The sponsor must address product quality issues, resolve facility inspection deficiencies (including providing the date of the facility's response to FDA Form 483 and potentially undergoing reinspection), revise prescribing information and labeling to conform with FDA regulations and guidances, resubmit the proposed proprietary name, and provide a comprehensive safety update including new safety data from clinical studies, updated exposure information, and a summary of worldwide safety experience.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761356_20240412.pdf
odronextamab,"Regeneron Pharmaceuticals, Inc.","The application cannot be approved in its present form because a confirmatory trial for odronextamab for follicular lymphoma is required and is not considered to be underway. The current conduct and projected completion date of the OLYMPIA trials in follicular lymphoma do not provide sufficient assurance of timely completion of the trial(s). Additionally, a safety update is required.",efficacy,"The Agency has determined that a confirmatory trial is required to be underway for odronextamab for follicular lymphoma prior to approval. To support resubmission of the BLA, the sponsor must address this deficiency. After enrollment and analysis of Part 1 (safety run-in or dose-finding) is completed for the intended confirmatory trial(s) in follicular lymphoma, the sponsor should request a meeting with the Agency to discuss trial benchmarks (e.g., enrollment goals, site activation, proportion of primary endpoint events accrued, trial completion date) to allow measurement of the progress of the trial(s). The sponsor should demonstrate in the submission that milestones are appropriate and that, prior to approval, sufficient progress in the conduct of the confirmatory portion of the confirmatory trial(s) will be demonstrated to provide sufficient assurance of timely completion of the trial(s). Additionally, a safety update is required, including data from all nonclinical and clinical studies/trials, significant changes or findings in the safety profile, new safety data from studies/clinical trials, retabulation of reasons for premature trial discontinuation, case report forms and narrative summaries for subjects who died or discontinued due to adverse events, information on substantial changes in common adverse events, updated exposure information, a summary of worldwide safety experience, and English translations of current approved foreign labeling.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761303Original1_20240322.pdf
TX05,"Tanvex BioPharma USA, Inc.","The FDA cannot approve this application in its present form due to deficiencies identified during facility inspections and the need for a comprehensive safety update, including new safety data, updated exposure information, and worldwide safety experience. Additionally, there are requirements for updated prescribing information and carton/container labeling.",multiple,"The facility must provide satisfactory responses to the deficiencies identified during the pre-license inspection, including the date(s) of the facility's response to the FDA Form 483. A comprehensive safety update is required, including new safety data from clinical studies, retabulation of reasons for premature study discontinuation, case report forms for subjects who died or discontinued due to adverse events, information on changes in common adverse events, updated exposure information, a summary of worldwide safety experience, and English translations of foreign labeling. Updated prescribing information and carton/container labeling must also be submitted, conforming to FDA regulations and guidance.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761266_20250103.pdf
SHR-1210,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","The FDA issued a Complete Response Letter for SHR-1210 due to deficiencies in facility inspections, inability to complete clinical inspections due to travel restrictions, and pending issues with prescribing information, carton/container labeling, proprietary name, and safety update requirements.",multiple,"To gain approval, the sponsor must address deficiencies identified during pre-license facility inspections, including providing the date of the facility's response to FDA Form 483 and resolving related deficiencies. Clinical inspections (BIMO) will be deferred until resubmission. The sponsor must also resubmit the proposed proprietary name, provide a comprehensive safety update as described in 21 CFR 314.50(d)(5)(vi)(b) including new safety data from studies/clinical trials, retabulation of trial discontinuations, case report forms for deaths/serious adverse events, updated exposure information, and worldwide safety experience. All deficiencies must be fully addressed in a resubmission clearly marked 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761308_20240516.pdf
,Dr. Reddy's Laboratories SA,"The application cannot be approved in its present form due to unresolved issues from facility inspections and product quality concerns. Satisfactory resolution of objectionable conditions from the pre-license inspection is required, including compliance with cGMP. Additional comments on product quality (microbiology, drug substance, drug product) and safety updates are also noted.",manufacturing,"Satisfactory resolution of the remaining objectionable conditions from the pre-license inspection is required, which depends on FDA's determination that the facility has come into compliance with cGMP and may require re-inspection. The sponsor must also provide a safety update including data from all nonclinical and clinical studies, describe changes in safety profile, provide updated exposure information, and summarize worldwide safety experience. All deficiencies must be fully addressed in a resubmission marked 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761376_20240419.pdf
rebisufligene etisparvovec,Ultragenyx Pharmaceutical Inc.,"The FDA issued a Complete Response Letter for rebisufligene etisparvovec due to deficiencies identified during pre-license inspections (PLI) at Ultragenyx Pharmaceutical Inc. The responses to Form FDA 483 observations did not sufficiently address the noted deficiencies, and corrective actions were not comprehensive enough to address systemic issues. Additionally, the FDA is still evaluating clinical data to determine if it adequately supports the proposed indication, requiring updated safety and efficacy data.",multiple,"To gain future approval, Ultragenyx Pharmaceutical Inc. must address the manufacturing deficiencies identified during the pre-license inspections, ensuring that corrective actions are comprehensive and address systemic issues. This may require additional review and verification during a follow-up inspection. Furthermore, the company needs to provide updated safety and efficacy data, including specific clinical measures (Bayley Scales, Vineland Adaptive Behavioral Scales, MRI results, and CSF biomarkers) from all patients treated with the investigational product, from 30 days prior to resubmission. The resubmission must fully address all listed deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA125845_20250707.pdf
EG12014,Sandoz Inc.,"The application cannot be approved in its present form due to deficiencies related to product quality (CMC Microbiology) and facility inspections. Specifically, the drug product manufacturing facility had deficiencies noted during a CGMP inspection and pre-license inspection (PLI), and satisfactory responses to these deficiencies are required. Additionally, there are comments on prescribing information, carton and container labeling, proprietary name, and a requirement for a safety update.",manufacturing,"The facility must provide satisfactory responses to the deficiencies noted during the CGMP and pre-license inspections to the FDA office indicated on the FDA 483. The FDA's determination of satisfactory responses will depend on a finding that the facility has come into compliance with CGMP and has addressed all deficiencies. A CGMP reinspection and/or additional PLI may be needed. The complete response should include the date(s) of the facility's response(s) to the FDA Form 483. The sponsor also needs to provide a safety update including data from all nonclinical and clinical studies, describe significant changes in the safety profile, present new safety data from clinical studies, retabulate reasons for premature study discontinuation, provide case report forms and narrative summaries for subjects who died or discontinued due to adverse events, describe changes in common adverse events, provide updated exposure information, summarize worldwide safety experience, and provide English translations of current approved foreign labeling. The resubmission must fully address all deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761271_20241205.pdf
INTP1,Accord BioPharma Inc.,"The Complete Response Letter (CRL) for INTP1 was issued due to unresolved deficiencies identified during facility inspections of the drug substance and drug product manufacturing facility. Additionally, there are pending issues related to prescribing information, carton and container labeling, proprietary name, and a requirement for a safety update.",manufacturing,"To gain future approval, Accord BioPharma Inc. must provide satisfactory responses to the deficiencies identified during the facility inspections, including the date(s) of the facility's response to the FDA Form 483. They also need to address issues with prescribing information, carton and container labeling, resubmit the proposed proprietary name, and provide a comprehensive safety update that includes new safety data from clinical studies, retabulation of adverse events, case report forms for deaths and serious adverse events, updated exposure information, and a summary of worldwide safety experience.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761027_20250626.pdf
NNC0148-0287 injection,Novo Nordisk Inc.,"The FDA issued a Complete Response Letter for NNC0148-0287 injection due to deficiencies identified during facility inspections and an unfavorable benefit-risk balance for glycemic control in adults with type 1 diabetes, primarily due to an unacceptably higher risk of clinically meaningful hypoglycemia without evidence of relative improvement in hemoglobin a1c reduction or other benefits compared to available therapy. The ONWARDS 6 study showed a significantly higher incidence and event rate of level 2 or level 3 hypoglycemia with NNC0148-0287.",multiple,"The company must provide satisfactory responses to deficiencies identified during facility inspections, including the date(s) of the facility's response to the FDA Form 483. For the clinical deficiency, new clinical data is required to demonstrate a favorable benefit-risk for NNC0148-0287 in subjects with type 1 diabetes. The FDA recommends a post-action meeting to discuss a potential new glycemic control clinical study that optimizes dosing and titration algorithms and assesses other patient-important outcomes. Additionally, a safety update including data from all nonclinical and clinical studies/trials of the product, regardless of indication, dosage form, or dose level, must be submitted, detailing any significant changes or findings in the safety profile and presenting new and retabulated safety data.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761326_20240710.pdf
rivoceranib,"Elevar Therapeutics, Inc.",The safety and effectiveness of rivoceranib has only been established in combination with SHR-1210. The FDA will not approve rivoceranib until a regulatory approval action is issued for SHR-1210.,efficacy,"A regulatory approval action must be issued for SHR-1210. The applicant must also address labeling deficiencies, including updating content of labeling in SPL format and resubmitting the proposed proprietary name.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA216586_20250320.pdf
"Abacavir, Lamivudine, Lopinavir, and Ritonavir Oral Granules","Cipla USA, Inc.",The application cannot be approved due to deficiencies found during a surveillance inspection of the manufacturing facility. Satisfactory resolution of these deficiencies is required.,manufacturing,"Satisfactory resolution of the manufacturing facility deficiencies is required. Additionally, experimental details need to be provided. A resubmission must fully address all deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA210168_20240322.pdf
"Abacavir, Lamivudine, Lopinavir, and Ritonavir Oral Granules","Cipla USA, Inc.","The application cannot be approved in its present form due to deficiencies related to product quality, prescribing information, and carton and container labeling.",multiple,"The applicant must resubmit the application addressing all deficiencies related to product quality, prescribing information, and carton and container labeling. The resubmission must be clearly marked as 'RESUBMISSION' and state that it is a complete response to the outlined deficiencies. A meeting or teleconference can be requested to discuss the steps needed for approval.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA210168_20250620.pdf
nilotinib capsules,Sun Pharmaceutical Industries Limited,"The application cannot be approved in its present form due to deficiencies related to product quality, prescribing information, carton and container labeling, medication guide, proprietary name, facility inspections, and safety update.",multiple,"The applicant must address deficiencies related to product quality, revise prescribing information and labeling, add a specific statement to the medication guide, resubmit the proposed proprietary name, ensure satisfactory responses to facility inspection deficiencies, and provide a comprehensive safety update including new safety data and analyses. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215644_20250625.pdf
scopolamine nasal gel,"Defender Pharmaceuticals, Inc","The application cannot be approved in its present form due to issues related to product quality, human factors (user interface and potential for medication errors), and insufficient efficacy data for the proposed indication.",multiple,"The sponsor needs to address product quality issues, implement user interface revisions and design modifications to promote safe and effective use, provide data demonstrating the mitigations work, and provide additional clinical data to support the demonstration of safety and effectiveness for the prevention of nausea induced by motion. Additionally, updates to prescribing information, carton and container labeling, proprietary name, and a safety update are required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA214315_20240125.pdf
TVB-009,"Teva Pharmaceuticals, Inc.","The CRL for TVB-009 is due to deficiencies identified during facility inspections, issues with prescribing information and labeling, and the need for a comprehensive safety update including a Risk Evaluation and Mitigation Strategy (REMS).",multiple,"To gain future approval, Teva Pharmaceuticals, Inc. must address facility inspection deficiencies, provide satisfactory responses to these deficiencies, potentially undergo an onsite pre-license inspection (PLI), submit updated prescribing information and labeling that conforms to FDA regulations and guidance, resubmit the proposed proprietary name, and provide a comprehensive safety update including new safety data, retabulations of study discontinuations, case report forms for deaths and serious adverse events, updated exposure information, and a summary of worldwide safety experience. All deficiencies must be fully addressed in a resubmission within one year.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761385_20250730.pdf
dasatinib tablets,Xspray Pharma AB,"The labeling comprehension studies did not show that the proposed labeling enables safe treatment switching between two dasatinib products and safe treatment initiation. The risk mitigation strategy of adding a descriptor after the product name did not prevent medication errors. The FDA is unable to generate adequate labeling for safe use for the proposed indications. Additionally, there are deficiencies related to product quality and facility inspections.",multiple,"The sponsor needs to consider other risk mitigation strategies for the established name nomenclature and labeling to facilitate safe treatment switching and initiation. They are highly recommended to request a meeting with the Agency prior to initiating additional studies evaluating other risk mitigation strategies. The sponsor must also address product quality deficiencies and provide satisfactory responses to facility inspection deficiencies, including a safety update with new safety data and retabulations.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA216195_20240725.pdf
Reproxalap Ophthalmic Solution,"Aldeyra Therapeutics, Inc.","The application failed to demonstrate efficacy in adequate and well-controlled studies for treating ocular symptoms associated with dry eyes due to a lack of substantial evidence and concerns with the data interpretation from Study 030, including methodological issues and statistical significance.",efficacy,"Conduct at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye, without making changes to the protocol or statistical analysis plan after the first subject is enrolled without FDA agreement. Also, provide a safety update and resubmit the proposed proprietary name.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA216442_20250402.pdf
SI-6603 injection,Seikagaku Corporation,"The application cannot be approved in its present form due to deficiencies identified during facility inspections and product quality microbiology. Additionally, a safety update is required, and the proposed proprietary name review has been terminated.",multiple,"Satisfactory responses from the facility regarding deficiencies identified during pre-license inspection are needed. A comprehensive safety update, including new safety data from studies/clinical trials, retabulation of adverse events, and updated exposure information, must be provided. The proposed proprietary name needs to be resubmitted after all application deficiencies are addressed.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761393_20250311.pdf
bendamustine injection,BendaRx USA Corporation,"The FDA cannot approve this application in its present form due to deficiencies in establishing a nonclinical bridge between the proposed drug product and listed drugs (LDs), specifically regarding differences in safety/tolerability and a lack of a pharmacokinetic (PK) bridge. The application is a 505(b)(2) application.",multiple,"To resolve the deficiencies, the sponsor needs to conduct a comparative bioavailability/bioequivalence (BA/BE) study in humans to demonstrate that formulation differences between the proposed drug product and the LDs do not impact overall PK/disposition and safety. The design of this study, including the statistical analysis plan, should be discussed with the FDA prior to initiation. Additional nonclinical safety/tolerability and/or PK data could be supportive. The sponsor also needs to address prescribing information, carton and container labeling, proprietary name, and provide a safety update including new safety data, retabulation of adverse events, and updated exposure information.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215291_20240117.pdf
,Accord BioPharma Inc.,"The FDA cannot approve this application in its present form due to deficiencies found during facility inspections and issues related to product quality, prescribing information, carton and container labeling, medication guide, risk evaluation and mitigation strategy (REMS), proprietary name, and safety update requirements.",multiple,"The applicant must address deficiencies from facility inspections by providing satisfactory responses to the FDA Form 483, resolve product quality issues, submit revised prescribing information conforming to FDA regulations, update carton and container labeling, add a required statement to the medication guide, continue discussions on the proposed REMS, resubmit proposed proprietary names, and provide a comprehensive safety update including new clinical data and worldwide experience.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761424_20250313.pdf
"(amino acids, dextrose and lipid injectable emulsion)","Fresenius Kabi USA, LLC","The application cannot be approved in its present form due to nonclinical, product quality, proprietary name, and safety deficiencies, as well as issues with prescribing information and carton/container labeling.",multiple,"The sponsor must address all identified deficiencies related to nonclinical data, product quality, proprietary name, safety updates (including new safety data, adverse event tabulations, and case reports), prescribing information, and carton/container labeling. A complete resubmission addressing all issues is required within one year, or an extension must be requested. The product cannot be marketed until written approval is received.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215818_20250425.pdf
sotagliflozin tablets,"Lexicon Pharmaceuticals, Inc.",The data submitted are not sufficient to support a favorable benefit-risk assessment for sotagliflozin for the proposed indication as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus (T1D) and chronic kidney disease (CKD). The risk of Diabetic Ketoacidosis (DKA) was unacceptably high given the comparatively modest benefits attributable to improvements in glycemic control and uncertainties about non-glycemic benefits.,safety,"Prospective clinical data demonstrating an acceptable risk of DKA with use of sotagliflozin would constitute one path forward. This could involve a prospective, pragmatic open-label randomized clinical safety trial with a standard-of-care active comparator arm, or potentially a single-arm study with an external control. The safety data collection could be largely limited to rigorous collection of data associated with DKA events and other serious adverse events. Additional glycemic control data in patients with T1D would be necessary to support dosing recommendations in patients with T1D and eGFR <60 ml/min/1.73mÂ². The sponsor needs to provide a safety update including data from all nonclinical and clinical studies/trials, describe significant changes in safety profile, present new and combined safety data, retabulate reasons for premature trial discontinuation, and provide case reports for deaths or discontinuations due to adverse events.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA210934_20241220.pdf
fosfomycin for injection,Meitheal Pharmaceuticals Inc.,"The FDA cannot approve this application in its present form due to deficiencies identified during a pre-approval inspection of the manufacturing facility, which adversely impact the facility's ability to perform designated functions. Additionally, there are deficiencies related to prescribing information, carton and container labeling, proprietary name, and a required safety update.",multiple,"The facility must provide satisfactory responses to the deficiencies identified during the pre-approval inspection. The complete response resubmission should include the date(s) of the facility's response(s) to the FDA Form 483. The FDA will evaluate the resolution of inspection deficiencies upon receipt of the complete response, which may include re-inspection. The sponsor must also address deficiencies related to prescribing information, carton and container labeling, proprietary name, and provide a comprehensive safety update including new safety data, retabulations of adverse events, case report forms for deaths and serious adverse events, updated exposure information, and worldwide safety experience. All deficiencies listed in the letter must be fully addressed in a resubmission clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA212271_20241211.pdf
rivoceranib tablet,"Elevar Therapeutics, Inc.","The application for rivoceranib tablet cannot be approved because its safety and effectiveness have only been established in combination with SHR-1210, which has not yet received regulatory approval. Additionally, the FDA was unable to complete all required Bioresearch Monitoring (BIMO) clinical inspections due to travel restrictions, and these inspections are deferred until resubmission. The proposed labeling for prescribing information, carton, and container is also reserved until the application is otherwise adequate.",multiple,"To gain future approval, rivoceranib will not be approved until a regulatory approval action is issued for SHR-1210. All Bioresearch Monitoring (BIMO) clinical inspections must be completed upon resubmission. The sponsor must also address deficiencies related to proprietary name, provide a safety update including new safety data, retabulation of trial discontinuations, case report forms for deaths and serious adverse events, and updated exposure information. They also need to provide a summary of worldwide safety experience and English translations of foreign labeling. The sponsor must resubmit the application addressing all deficiencies within one year, clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA216586_20240516.pdf
amivantamab and hyaluronidase injection,"Janssen Biotech, Inc.","The application cannot be approved in its present form due to deficiencies identified during pre-license inspection of the drug product manufacturing facility, issues with prescribing information and carton/container labeling, and a need for a safety update and further clinical pharmacology analysis.",multiple,"The company must provide satisfactory responses to deficiencies identified during the manufacturing facility inspection, submit updated draft labeling (prescribing information and carton/container labeling) conforming to regulations, include a comprehensive safety update with new and retabulated safety data, and re-analyze anti-amivantamab antibodies data. A final determination on clinical pharmacology acceptability is contingent upon a pending site inspection.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761433_20241213.pdf
Atazanavir Sulfate and Ritonavir Tablets,Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc.,"The Complete Response Letter (CRL) for Atazanavir Sulfate and Ritonavir Tablets was issued due to deficiencies related to manufacturing facilities, including CGMP inspection findings and data reliability concerns from the original drug product manufacturing facility. There are also concerns regarding the bioequivalence/bioavailability data due to these reliability issues, and product quality issues.",manufacturing,"To gain future approval, the facility must provide satisfactory responses to FDA Form 483 deficiencies, come into compliance with CGMP, and potentially undergo re-inspection and a PAI. The company needs to submit the entire CMC data package for the new bio-batch to be used in a new BE study, and address data reliability concerns by conducting a new bioequivalence (BE) study using batches manufactured at the new drug product manufacturing site. Additionally, product quality issues and labeling comments need to be addressed.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA205508_20250728.pdf
(lidocaine) topical system,"MEDRX USA, Inc.","The FDA cannot approve this application in its present form due to deficiencies in nonclinical data, prescribing information, carton and container labeling, proprietary name, and safety update requirements. The letter details specific issues in each of these areas that need to be addressed.",multiple,"The applicant must address all deficiencies listed in the CRL, including providing a comprehensive safety update with new and re-tabulated safety data, addressing nonclinical issues, revising labeling, and resubmitting the proposed proprietary name. The resubmission must be clearly marked as 'RESUBMISSION' and state that it is a complete response to all deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215029_20240711.pdf
Bendamustine Hydrochloride injection,Accord Healthcare Inc.,The FDA cannot approve this application in its present form due to deficiencies identified during surveillance inspections of two manufacturing facilities and the need for a safety update with new data and revised labeling information.,multiple,"Satisfactory resolution of observations from surveillance inspections of both manufacturing facilities is required. A comprehensive safety update must be submitted, including detailed changes in the safety profile, new safety data from studies/clinical trials, tabulations of new and original safety data, comparisons of adverse event frequencies, retabulation of reasons for premature trial discontinuation, and case report forms/narrative summaries for deaths and serious adverse events. Updated exposure information and worldwide safety experience, including English translations of foreign labeling, are also required. The proposed labeling will be reviewed once the application is otherwise adequate.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215749_20240307.pdf
nilotinib capsules,Sun Pharmaceutical Industries Limited,"The application cannot be approved in its present form due to deficiencies related to prescribing information, carton and container labeling, medication guide, proprietary name, facility inspections (CGMP and PAI), and safety update requirements.",multiple,"The sponsor must address deficiencies related to prescribing information (labeling content and format), carton and container labeling (Medication Guide statement), proprietary name (resubmit), facility inspections (satisfactory responses to FDA 483 observations, CGMP compliance, potential reinspection), and provide a comprehensive safety update including new safety data, retabulations, case reports for deaths/serious adverse events, updated exposure information, and worldwide safety experience. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215644_20241025.pdf
"amino acids with electrolytes, dextrose, and lipid injectable emulsion","Fresenius Kabi USA, LLC","The FDA cannot approve this application in its present form due to deficiencies identified in nonclinical, product quality, proprietary name, and safety aspects. The letter details specific requirements for a safety update, including new safety data, retabulation of adverse events, and case reports for serious adverse events or deaths.",multiple,"The sponsor must address all deficiencies listed in the CRL, including providing a comprehensive safety update with new safety data, retabulated adverse event frequencies, and case reports for serious adverse events or deaths. They also need to resubmit proposed proprietary names and address nonclinical and product quality issues. The resubmission must be clearly marked as 'RESUBMISSION' and fully address all deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA214610_20241211.pdf
CT-P42,"CELLTRION, Inc.","The application cannot be approved in its present form due to product quality issues, specifically related to facility inspections and compliance with CGMP. The FDA identified deficiencies during CGMP and pre-license inspections, requiring satisfactory responses and potential re-inspections to confirm compliance.",manufacturing,"The facility must provide satisfactory responses to the deficiencies identified during CGMP and pre-license inspections (FDA Form 483). The facility needs to come into compliance with CGMP and address all specific deficiencies. A CGMP reinspection and/or additional pre-license inspection may be required to confirm satisfactory resolution of these issues. The complete response should include the date(s) of the facility's responses to the FDA Form 483. Additionally, a safety update including data from all nonclinical and clinical studies, and updated prescribing information and labeling, are required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761377_20240627.pdf
,"CELLTRION, Inc.","The FDA issued a Complete Response Letter for the Biologics License Application (BLA) due to deficiencies identified during facility inspections. Satisfactory responses to these deficiencies are required for approval. Additionally, the letter includes comments and recommendations regarding prescribing information, carton and container labeling, proprietary name, and safety updates, which are not considered approvability issues but need to be addressed.",manufacturing,"The facility must provide satisfactory responses to the deficiencies identified during the pre-license inspection (FDA 483). The complete response should include the date(s) of the facility's response(s) to the FDA Form 483. The FDA will evaluate the application's approvability and the resolution of inspection deficiencies upon receipt of the complete response, which may include a re-inspection of the facility. The company must work with the facility to resolve the related deficiencies. Additionally, the company needs to submit updated prescribing information, carton and container labeling, resubmit the proposed proprietary name, and provide a comprehensive safety update addressing all new data and changes in the safety profile.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_BLA761377_20250326.pdf
elamipretide injection,Stealth BioTherapeutics Inc.,"The FDA issued a Complete Response Letter for elamipretide injection due to insufficient evidence of effectiveness for traditional or accelerated approval, and deficiencies at the drug product manufacturing facility. The clinical studies (SPIBA-201 Part 1 and Part 2, and SPIBA-001) did not demonstrate a meaningful treatment effect, with concerns about bias and the reliability of surrogate endpoints. Manufacturing deficiencies also need to be resolved.",multiple,"To gain future approval, the sponsor needs to resolve manufacturing deficiencies identified during the CGMP inspection. For efficacy, the FDA suggests pursuing accelerated approval using muscle strength of the knee extensors as an intermediate clinical endpoint, provided the sponsor can demonstrate its reasonable likelihood to predict clinical benefit in Barth syndrome (BTHS) and propose a confirmatory postmarketing clinical trial. The sponsor is encouraged to request an End-of-Review meeting to discuss this approach. Additionally, postmarketing studies related to carcinogenicity and drug-drug interactions are required if the NDA is approved.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215244_20250515.pdf
midomafetamine capsules,Lykos Therapeutics,"The application does not provide substantial evidence of effectiveness or establish the safety of the product to support the approval of midomafetamine for the treatment of posttraumatic stress disorder (PTSD). Issues include insufficient collection of information on positive/favorable events, unreported adverse events, concerns about the reliability of safety data, lack of demonstrated durable effect, and potential for selection bias impacting generalizability and interpretability of study results.",multiple,"Conduct a new clinical trial to assess the durability of effect and adequately characterize the safety of midomafetamine. This trial should be a randomized, double-blind study with initial treatment sessions followed by blinded long-term follow-up with pre-specified criteria for retreatment. The study design must address: demonstrating durability of effect (blinded follow-up, criteria for retreatment, monthly assessments), minimizing potential for bias (exclude/minimize prior MDMA use, assess participant expectancy, assess unblinding, consider low-dose control arm), and adequately characterizing safety (capture all abuse-related adverse events, develop standardized discharge criteria). Additionally, consider an independent third-party data audit of all study records and reports to identify unreported/under-reported adverse events and ensure robustness of findings from MAPP1 and MAPP2 studies. Address data gaps in future resubmission including routine laboratory assessments, vital signs, hERG assessment, and dedicated pharmacodynamic (ECG) study. Consider drug-drug interaction studies, PK studies in patients with impaired hepatic/renal function, clinical lactation studies, and pre- and post-natal development studies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA215455_20240808.pdf
Darunavir and Ritonavir Tablets,"Laurus Generics, Inc.","The FDA cannot tentatively approve this application in its present form due to product quality issues, specifically related to manufacturing and stability studies. Additionally, there are comments reserved on prescribing information and container labeling until the application is otherwise adequate.",manufacturing,"The applicant needs to address the product quality issues, including those related to manufacturing and stability studies. They should also review and adequately address the prescribing information and container labeling as per FDA guidelines. A resubmission fully addressing all deficiencies is required, clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217719_20250310.pdf
hydrocortisone sodium phosphate injection,"Antares Pharma, Inc.","The drug product manufacturing site requires satisfactory resolution of observations before this NDA may be approved. Additionally, the proposed prescribing information and proprietary name require revisions and resubmission.",manufacturing,"Satisfactory resolution of observations at the drug product manufacturing site, submission of revised draft labeling that is responsive to electronic communication and conforms to regulations and guidances, and resubmission of the proposed proprietary name after all application deficiencies are addressed.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218026_20240816.pdf
furosemide injection,"SQ Innovation, Inc.","The application cannot be approved in its present form due to deficiencies related to product quality, device, prescribing information, and safety updates.",multiple,"The applicant needs to address deficiencies in product quality, device, prescribing information, and provide a comprehensive safety update. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'. The applicant may request a meeting or teleconference to discuss the required steps for approval.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217294_20240112.pdf
sodium bicarbonate in water for injection,Baxter Healthcare Corporation,"The application cannot be approved in its present form due to deficiencies related to product quality, prescribing information, carton and container labeling, and safety updates.",multiple,"The applicant must address deficiencies in product quality, update prescribing information to conform with regulations and guidance, provide a safety update including new data and translations of foreign labeling, and address carton and container labeling issues. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218524_20240329.pdf
bendamustine hydrochloride injection,Accord Healthcare Inc.,"The application cannot be approved in its present form due to deficiencies identified during a surveillance inspection of manufacturing facilities and the need for a comprehensive safety update, as well as labeling issues.",multiple,"Satisfactory resolution of manufacturing facility deficiencies, a comprehensive safety update including new data and analyses, and addressing labeling issues are required for future approval. The resubmission must fully address all deficiencies and be clearly marked as a 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA216987_20240510.pdf
leve (naproxen sodium) capsule,Bayer HealthCare LLC,"The application cannot be approved in its present form due to inadequate nonclinical data, product quality issues, and facility inspection deficiencies.",multiple,"The applicant must provide adequate nonclinical data, address product quality issues, resolve facility inspection deficiencies, and submit a safety update with new safety data and analyses. A resubmission must fully address all deficiencies listed in the letter.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218506_20240613.pdf
octreotide hydrochloride extended-release injection,Camurus AB,"The application cannot be approved due to deficiencies identified during a Current Good Manufacturing Practices (CGMP) inspection of a facility listed in the application, and issues with prescribing information, carton and container labeling, proprietary name, and safety update requirements.",multiple,"The applicant must address all deficiencies, including satisfactory responses from the manufacturing facility regarding CGMP compliance (which may require re-inspection and pre-approval inspection), submit revised prescribing information conforming to regulations, update carton and container labeling, resubmit the proposed proprietary name, and provide a comprehensive safety update with new and retabulated safety data. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218600_20241021.pdf
"naproxen sodium, dextromethorphan hydrobromide, guaifenesin extended-release (ER) tablet",RB Health (US) LLC,"The application was not approved due to insufficient evidence to support the proposed 12-hour duration of action and dosing regimen for the ER product. The submitted pharmacokinetic data, while showing bioequivalence to approved drugs, did not adequately support the extended dosing interval for naproxen. Scientific literature and indirect bridging data provided were also deemed insufficient to support the proposed 12-hour dosing interval.",efficacy,"To gain future approval, the applicant may consider providing clinical efficacy data to support a 12-hour duration of use in a relevant patient population, or conducting a relative bioavailability study to establish a scientific bridge between the proposed product and Aleve-D Sinus and Cold (naproxen sodium 220 mg; pseudoephedrine HCl 120 mg extended-release tablet [NDA 021076]). Additionally, a safety update is required, including new safety data from studies/trials, updated tabulations of adverse events, and a summary of worldwide experience.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217338_20240726.pdf
phenobarbital sodium injection,"Hikma Pharmaceuticals USA, Inc.","The application does not provide analyzable efficacy and safety datasets for independent FDA review, particularly regarding the 'NEOLEV2' study. Additionally, there is an inadequate assessment of the abuse potential of phenobarbital, and deficiencies were noted during facility inspections.",multiple,"The applicant must provide analyzable efficacy and safety datasets, including a more detailed presentation of the NEOLEV2 study data, and discuss the contents and formats of this information with the FDA. A comprehensive abuse potential assessment for phenobarbital is required, including appropriate data related to abuse and dependence. Satisfactory resolution of observations from facility inspections is also necessary. A safety update with new safety data from clinical studies/trials, including detailed changes, discontinuations due to adverse events, and updated exposure information, must be submitted. The applicant should also ensure that the proposed labeling conforms to regulatory requirements.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218258_20240123.pdf
floretyrosine F 18,Telix Pharmaceuticals (US) Inc.,"The clinical data submitted in this application did not provide substantial evidence of effectiveness for floretyrosine F 18. The efficacy study, 18F-TLX101-CDx-203, was considered adequate and well-controlled but demonstrated borderline diagnostic performance with lower bounds of the 95% confidence intervals ranging from 58% to 73% for sensitivity and from 36% to 51% for specificity across the three blinded central readers. In addition, it was a single center study and had potential for bias in reference standard determination, further limiting its persuasiveness. Evidence provided as confirmatory evidence of effectiveness was not sufficiently strong to complement study 18F-TLX101-CDx-203. Four studies were examined as confirmatory evidence, including one re-read of images obtained from expanded access use of floretyrosine F 18, GBM-RET-01, and three published retrospective studies. GBM-RET-01 used a higher administered activity than intended for labeling, had potential for unblinding of the reference standard evaluators, and more than 10% of patients with missing reference standard results. The remaining studies shared design issues including use of different image evaluation methods than intended for labeling and lack of per reader results. Additionally, a safety update is required.",multiple,"To address these issues, a second adequate and well-controlled efficacy study, which could be conducted in the same patient population or a closely related condition, or other robust confirmatory evidence of efficacy is necessary. Optimization of the administered dose of floretyrosine F 18 could also be considered. A safety update is required, including detailed descriptions of significant changes or findings in the safety profile, new safety data from studies/clinical trials, retabulations of new safety data combined with original data, comparisons of adverse event frequencies, retabulation of reasons for premature trial discontinuation, case report forms and narrative summaries for subjects who died or did not complete a trial due to adverse events, information on substantial changes in common adverse events, updated exposure information, and a summary of worldwide safety experience. The proposed proprietary name, prescribing information, and carton and container labeling will be reviewed once the application is otherwise adequate.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218592_20250425.pdf
carbidopa and levodopa injection,"NeuroDerm, Ltd.","The application for carbidopa and levodopa injection was not approved due to an inadequate scientific bridge for carbidopa PK exposure between Engolce and Sinemet, leading to safety concerns regarding higher carbidopa exposure. Additionally, the clinical studies were not designed to characterize QTc interval effects, and there are unresolved deficiencies from pre-approval facility inspections.",multiple,"The applicant needs to conduct a thorough QT (TQT) study to assess potential effects of Engolce on the QTc interval, considering the carbidopa exposure from Engolce and any additional carbidopa/levodopa products. They must also provide satisfactory responses to deficiencies identified during pre-approval facility inspections, including addressing issues related to drug-drug interactions and providing clear labeling instructions for converting to Engolce from other carbidopa/levodopa products. A safety update with new safety data and revised tabulations of adverse events is also required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218317_20240524.pdf
Floretyrosine F 18 Injection,University of California San Francisco,The application was not approved due to insufficient evidence of effectiveness for floretyrosine F 18. The primary efficacy study showed borderline diagnostic performance and had potential for bias. Confirmatory studies were also not sufficiently strong due to design issues and missing data.,efficacy,"To gain future approval, a second adequate and well-controlled efficacy study is necessary, which could be conducted in the same or a closely related patient population, or other robust confirmatory evidence of efficacy. Optimization of the administered dose of floretyrosine F 18 could also be considered. Additionally, a safety update including data from all nonclinical and clinical studies/trials of floretyrosine F 18, regardless of indication, dosage form, or dose level, is required. This safety update should detail any significant changes or findings in the safety profile, incorporate new safety data into sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, and provide updated exposure information and a summary of worldwide experience on the safety of floretyrosine F 18.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218353_20250425.pdf
sirolimus cream,AFT Pharmaceuticals Ltd,"The FDA issued a Complete Response Letter for the new drug application for sirolimus cream due to deficiencies in product quality, microbiology, drug product manufacturing process, facility inspections, clinical data, prescribing information, carton and container labeling, medication guide, proprietary name, and an incomplete safety update. The application cannot be approved in its present form.",multiple,"The sponsor must address deficiencies related to product quality, microbiology, drug product manufacturing process, facility inspections, clinical data, prescribing information, carton and container labeling, medication guide, proprietary name, and provide a safety update. Specifically, satisfactory resolution of observations from facility inspections is required, and additional adequate and well-controlled clinical trials may be needed depending on the data provided. The proposed proprietary name must be resubmitted after all application deficiencies are addressed.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218528_20240125.pdf
phenylephrine hydrochloride in sodium chloride injection,"Amneal EU, Limited","The application cannot be approved in its present form due to deficiencies identified during a CGMP inspection of a facility, issues with prescribing information, carton and container labeling, and a need for a safety update.",multiple,"The facility must provide satisfactory responses to the FDA 483 deficiencies and come into compliance with CGMP, which may require re-inspection. A preapproval inspection (PAI) and CGMP surveillance inspections must have satisfactory outcomes. The sponsor must also provide a safety update including all nonclinical and clinical study data, describe changes in the safety profile, incorporate new safety data into adverse event sections, and provide updated exposure information and worldwide safety experience. English translations of current approved foreign labeling must also be submitted. All deficiencies must be fully addressed in a resubmission.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218345_20250402.pdf
Naloxone hydrochloride nasal powder,Orexo AB,"The CRL was issued due to deficiencies related to the device, specifically that the final finished version of the device was not considered in verification, reliability, stability, and shipping verification tests, with noted differences between tested and commercial versions. Additionally, human factors validation study results showed that the user interface does not support safe and effective use, with participants failing to depress the plunger and believing they had successfully administered a dose when they had not. Other issues include pending review of prescribing information and carton/container labeling until other deficiencies are resolved, and a requirement for a safety update.",multiple,"The sponsor needs to implement user interface revisions and design modifications to promote the safe and effective use of the proposed product, and provide data demonstrating that, with these mitigations, the product user interface can be used safely and effectively to deliver the intended dose of drug substance. They should submit their HF validation study protocol, along with the redesigned user interface, for review and feedback. Additionally, a safety update including data from all nonclinical and clinical studies/trials of the drug is required, along with updated safety data presentations and summaries as detailed in the letter.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217433_20240715.pdf
Epinephrine injection,Accord Healthcare Inc.,The FDA has issued a Complete Response Letter for the Epinephrine injection NDA due to deficiencies found during facility inspections and issues related to product quality. The application cannot be approved in its present form.,manufacturing,"Satisfactory resolution of the deficiencies identified during the manufacturing facility inspection is required. The sponsor also needs to address product quality issues and provide an updated safety profile including new safety data, retabulation of adverse events, case report forms for deaths/discontinuations due to adverse events, updated exposure information, and a summary of worldwide safety experience. Labeling comments will be provided once the application is otherwise adequate.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218470_20240130.pdf
phenylephrine hydrochloride in sodium chloride injection,"Amneal EU, Ltd. c/o Amneal Pharmaceuticals of New York, LLC.","The FDA issued a Complete Response Letter for phenylephrine hydrochloride in sodium chloride injection due to deficiencies in product quality, nonclinical, and regulatory aspects. The letter indicates that the application cannot be approved in its present form and outlines issues related to manufacturing, safety updates, and labeling.",multiple,"The applicant must address deficiencies related to product quality, nonclinical data, and regulatory issues. This includes providing a safety update with detailed changes in the safety profile, new safety data from studies, updated tabulations of adverse events, case report forms for subjects who died or discontinued due to adverse events, updated exposure information, and a summary of worldwide safety experience. Additionally, the applicant needs to provide English translations of foreign labeling and address comments on prescribing information and carton/container labeling. A resubmission must fully address all deficiencies outlined in the letter.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218345_20240701.pdf
etripamil nasal spray,"Milestone Pharmaceuticals USA, Inc.","The FDA issued a Complete Response Letter for etripamil nasal spray due to deficiencies in product quality, an uncompleted preapproval inspection of the manufacturing facility, issues with the proprietary name, and requirements for a comprehensive safety update. The application cannot be approved in its current form.",multiple,"The sponsor must address deficiencies related to product quality, facility inspections, proprietary name, and safety updates. This includes completing a preapproval inspection of the manufacturing facility, resubmitting the proposed proprietary name, and providing a comprehensive safety update with new and retabulated safety data from clinical studies. All deficiencies must be fully addressed in a resubmission clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218571_20250327.pdf
nilotinib orally disintegrating tablets,"Nanocopoiea, LLC","The Complete Response Letter (CRL) for nilotinib orally disintegrating tablets cites multiple deficiencies. These include issues with clinical pharmacology, specifically a failed bioequivalence study and concerns regarding QT prolongation risk. Additionally, there are unresolved deficiencies from a pre-approval inspection of the manufacturing facility, and the proposed proprietary name is conditionally acceptable pending approval of the application.",multiple,"The sponsor must address deficiencies related to clinical pharmacology (bioequivalence, QT prolongation risk), provide a safety update with new clinical data, resolve manufacturing facility inspection deficiencies, and resubmit the proposed proprietary name. A complete response to all deficiencies is required, and a re-inspection of the facility may be necessary.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217379_20240614.pdf
furosemide injection,Baxter Healthcare Corporation,"The application cannot be approved in its present form due to product quality issues, and deficiencies in prescribing information, carton and container labeling, and safety updates.",multiple,"The applicant needs to address product quality issues, provide updated prescribing information in SPL format, update carton and container labeling, and submit a comprehensive safety update including new safety data from studies/clinical trials, and present tabulations of new safety data combined with original application data. They also need to provide case report forms and narrative summaries for subjects who died or discontinued due to adverse events, describe substantial changes in incidence of common/less serious/serious adverse events, provide updated exposure information, provide a summary of worldwide experience, and provide English translations of current approved foreign labeling.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218408_20240327.pdf
20% soybean oil emulsion,ResQ Pharma,"The application was not approved due to deficiencies in clinical and biopharmaceutics data, human factors validation study results, and regulatory issues regarding the adequacy of published literature to support safety and effectiveness, particularly concerning the scientific bridge between Intralipid and Nutrilipid for the treatment of LAST in both adult and pediatric patients. There are also discrepancies in the proposed indication and dosing regimen.",multiple,"The sponsor needs to provide additional data to demonstrate comparable drug capture capability between Nutrilipid 20% and Intralipid 20%, justify why physicochemical differences do not affect in vivo performance, and support the applicability of existing safety and effectiveness data. They must also provide detailed information on their literature search strategy and methods, develop and implement additional risk controls for the human factors validation study, and address discrepancies in the proposed indication and dosing regimen. A safety update with new clinical trial data and updated labeling information is also required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217382_20250602.pdf
dasiglucagon,"Zealand Pharma US, Inc.","The Complete Response Letter (CRL) for dasiglucagon was issued due to several deficiencies, including unresolved manufacturing issues related to current good manufacturing practice (CGMP) inspection findings, issues with the proposed prescribing information (labeling), and outstanding safety concerns, particularly regarding the drug's use in infants under 4.1 kg and premature infants. The FDA requires resolution of these issues before approval.",multiple,"To gain future approval, Zealand Pharma US, Inc. must address the following: 1. Resolve all deficiencies identified during the CGMP inspection, ensuring the facility comes into compliance. This may require a re-inspection and satisfactory outcomes from both a pre-approval inspection (PAI) and CGMP surveillance inspections. 2. Submit revised draft labeling that is responsive to FDA's electronic communication, using the Selected Requirement of Prescribing Information (SRPI) checklist, and providing updated content in structured product labeling (SPL) format. 3. Provide a comprehensive safety update, including detailed changes or findings in the safety profile, new safety data from clinical trials, and updated tabulations of adverse events (AEs) and serious adverse events (SAEs). This includes addressing the safety of dasiglucagon in infants under 4.1 kg and premature infants, providing justification for dosing recommendations, and clarifying the impact of age and body weight on dasiglucagon exposure. 4. Address additional comments regarding the use of infusion pumps in infants under 4.1 kg and the effect of renal impairment on dasiglucagon pharmacokinetics. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217724_20241008.pdf
cefepime for injection and taniborbactam for injection,"Venatorx Pharmaceuticals, Inc.","The FDA issued a Complete Response Letter for the New Drug Application (NDA) for cefepime for injection and taniborbactam for injection due to deficiencies in product quality, nonclinical data, prescribing information, carton and container labeling, proprietary name, safety update, and clinical pharmacology. The application cannot be approved in its present form.",multiple,"The sponsor needs to address deficiencies related to product quality, nonclinical data, prescribing information, carton and container labeling, proprietary name, safety update, and clinical pharmacology. This includes providing additional data, analyses, and revised labeling as detailed in the CRL. A resubmission must fully address all deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217556_20240222.pdf
glatiramer acetate (GA) Depot,Mapi Pharma Ltd.,"The application was not approved due to deficiencies in product quality (manufacturing), clinical/statistical issues regarding the interpretability and persuasiveness of efficacy findings, inadequate safety data, and concerns with the proposed combination product's compliance with manufacturing regulations.",multiple,"The sponsor needs to address product quality issues, including satisfactory resolution of observations from the pre-approval inspection of the manufacturing facility. For clinical/statistical issues, a new adequate and well-controlled study demonstrating a significant treatment effect on a rigorously measured primary outcome is required, addressing concerns about relapse determination methodology, prolonged evaluation windows, unblinded investigators, lack of an independent Relapse Adjudication Committee, and absence of MRI in relapse evaluation. The sponsor must also provide a comprehensive safety evaluation with routine safety laboratory assessments and adequate ECG data, and ensure compliance with CGMP requirements for the combination product.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218223_20240308.pdf
roluperidone extended-release tablets,"Minerva Neurosciences, Inc","The NDA submission for roluperidone extended-release tablets for the treatment of negative symptoms of schizophrenia was not approved due to insufficient evidence of effectiveness, lack of data on concomitant antipsychotic administration, and lack of data to establish clinical meaningfulness of the change in negative symptoms. Additionally, the safety database for long-term use was inadequate, and the proposed strategy for identifying patients at risk of QTc prolongation was insufficient. Product quality deficiencies were also noted for both drug substance and drug product.",multiple,"Submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms. Provide additional data to demonstrate the safety and efficacy of roluperidone coadministered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose. Data from U.S. subjects will contribute to these additional efficacy and safety data. Discuss the design of any additional planned study or studies with the Agency prior to study initiation. Develop a strategy sufficient to reliably identify patients at greatest risk of QT interval prolongation with roluperidone. Ensure CYP2D6 phenotype assignments are consistent with current phenotyping and testing standards. Develop and obtain contemporaneous authorization of an in vitro companion diagnostic device to ensure robust pharmacogenomic test allele coverage and test accuracy to identify patients for treatment. Address product quality deficiencies for drug substance and drug product. Provide a safety update including data from all nonclinical and clinical studies/trials of the drug, detailing significant changes or findings in the safety profile, presenting new safety data from studies/clinical trials, tabulating new safety data combined with original application data, and comparing frequencies of adverse events. Present a retabulation of reasons for premature trial discontinuation, provide case report forms and narrative summaries for subjects who died or did not complete trials due to adverse events, describe information suggesting substantial change in incidence of common adverse events, provide updated exposure information, summarize worldwide safety experience, and provide English translations of current approved foreign labeling. Provide additional validity evidence for NSFS and PSP measures, including qualitative evidence from patients and caregivers, development of a conceptual framework, clinically meaningful change analyses, and additional psychometric analyses or evidence from literature. Ensure clear scoring algorithm and rationale for NSFS, evidence of known-groups validity, and analyses demonstrating item-level changes consistency. For PSP, conduct factor analyses and provide rationale for cut-off for dichotomization. Conduct qualitative interviews to assess meaningful change. Ensure best practices for translation of COAs. Provide detailed information regarding derivation of PSP scores when centralized raters are used.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA217002_20240226.pdf
dienogest and ethinyl estradiol tablets,"Chemo Research, S.L. c/o Exeltis USA, Inc.","The application for dienogest and ethinyl estradiol tablets cannot be approved due to an unacceptable benefit/risk profile. Review of the safety database from Study LPRI-424/303 clearly demonstrates a markedly increased risk of venous thromboembolism (VTE) rate. A higher VTE rate associated with the same dienogest and ethinyl estradiol (DNG/EE) combination as the proposed product, compared to other combination oral contraceptives (COCs) in the European postmarketing database, further substantiates an increased risk for the proposed fixed dose combination product. The benefit/risk profile for this COC product is unacceptable for an indication of prevention of pregnancy. Additionally, comments are reserved on the proposed labeling (prescribing information, carton, and container) because the application is otherwise inadequate.",safety,"The FDA is unable to recommend any further actions that would result in approval of this application. If the sponsor chooses to submit a new original NDA for a different COC product that would have a more favorable benefit/risk profile, the FDA would consider that product on its own merits.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA219029_20250529.pdf
Diazepam Injection,"Hospira, Inc.","The application cannot be approved in its present form due to deficiencies in product quality, nonclinical data, prescribing information, carton and container labeling, and an incomplete safety update.",multiple,"The applicant needs to address deficiencies related to product quality, nonclinical data, prescribing information, carton and container labeling, and provide a safety update including new safety data from studies/clinical trials, re-tabulation of trial discontinuations, case report forms for deaths/adverse events, updated exposure information, and a summary of worldwide safety experience. They must also provide English translations of current approved foreign labeling.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA219112_20250117.pdf
phenylephrine hydrochloride in sodium chloride injection,Hikma Pharmaceuticals USA Inc.,"The FDA cannot approve the application in its present form due to deficiencies related to product quality, prescribing information, carton and container labeling, proprietary name, and safety updates. The letter details specific issues within each of these categories that need to be addressed.",multiple,"The applicant must fully address all deficiencies listed in the CRL, including issues related to product quality, labeling (prescribing information, carton/container), proprietary name, and safety updates. A comprehensive safety update with new and retabulated data, case report forms for adverse events, and updated exposure information is required. The resubmission must be clearly marked as 'RESUBMISSION' and state that it is a complete response to the deficiencies. A meeting or teleconference with the FDA can be requested to discuss the required steps.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA219357_20241223.pdf
metoprolol tartrate,XTM Consulting LLC,The application cannot be approved in its present form due to deficiencies related to product quality and safety updates. The letter also mentions comments on prescribing information and carton/container labeling.,multiple,"The applicant must address all deficiencies related to product quality, provide a comprehensive safety update including new safety data from studies/clinical trials, retabulate reasons for premature trial discontinuation, provide case report forms and narrative summaries for subjects who died or discontinued due to adverse events, describe changes in common adverse events, provide updated exposure information, summarize worldwide safety experience, and provide English translations of approved foreign labeling. A resubmission must fully address all listed deficiencies and be clearly marked as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218698_20240612.pdf
oxylanthanum carbonate tablets,Unicycive Therapeutics Inc.,"The application cannot be approved in its present form due to deficiencies identified during facility inspections related to Current Good Manufacturing Practices (CGMP) and pre-approval inspection (PAI). Additionally, there are issues with prescribing information, carton and container labeling, proprietary name, and a need for a comprehensive safety update.",multiple,"The facility must provide satisfactory responses to deficiencies noted in the FDA Form 483, demonstrating compliance with CGMP. A CGMP reinspection and/or additional PAI may be required. The sponsor needs to address issues with prescribing information, carton and container labeling, resubmit the proprietary name, and provide a comprehensive safety update including new clinical data, retabulation of adverse events, and updated exposure information. All deficiencies must be fully addressed in a resubmission within one year.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218607_20250627.pdf
lamotrigine oral suspension,"OWP Pharmaceuticals, Inc.","The application cannot be approved in its present form due to deficiencies related to product quality, facility inspections, proprietary name, and safety updates.",multiple,"The sponsor must address deficiencies related to product quality, ensure the drug substance manufacturing facility is operational and ready for inspection, resubmit the proprietary name, and provide a comprehensive safety update including new safety data, retabulated adverse event frequencies, and updated exposure information. All deficiencies must be fully addressed in a resubmission.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218879_20250103.pdf
paclitaxel protein-bound particles for injectable suspension (albumin-bound),Accord Healthcare Inc.,"The application cannot be approved in its present form due to deficiencies in product quality, unresolved issues from facility inspections for both drug product and drug substance manufacturing facilities, and the need for a comprehensive safety update. The proposed labeling also requires further review once other issues are resolved.",multiple,"The sponsor must address deficiencies related to product quality, facility inspections, and provide a comprehensive safety update. Specifically, satisfactory resolution of observations from manufacturing facility inspections is required. A safety update must include detailed changes in the safety profile, retabulation of adverse events, case reports for deaths or discontinuations due to adverse events, updated exposure information, and a summary of worldwide safety experience. All listed deficiencies must be fully addressed in a resubmission.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218762_20240417.pdf
vatiquinone oral capsules,"PTC Therapeutics, Inc.","The application for vatiquinone oral capsules was not approved because the submitted data did not demonstrate substantial evidence of effectiveness for vatiquinone in the treatment of Friedreich's Ataxia (FA). The single controlled trial (MOVE-FA) was not capable of serving as an adequate and well-controlled study to provide substantial evidence of effectiveness. The study failed to show a statistically significant difference between vatiquinone and placebo for the primary and key secondary efficacy endpoints. Additionally, there were concerns regarding baseline imbalances, handling of missing data, and the robustness of exploratory analyses.",efficacy,"To address the deficiencies, data from a positive, adequate, and well-controlled study will be needed to establish the effectiveness of vatiquinone in the treatment of subjects with FA. A potential path would be to conduct a prospective randomized, controlled study in pediatric subjects with FA with change from baseline in USS as a primary endpoint. Additionally, adequate studies must be conducted to qualify multiple drug substance and drug product impurities.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA220049_20250818.pdf
irinotecan liposome injection,Conjupro Biotherapeutics Inc.,"The FDA issued a Complete Response Letter for the NDA due to deficiencies identified during facility inspections, inability to complete all Office of Study Integrity and Surveillance inspections due to travel restrictions, and requirements for a safety update including new safety data and updated information.",multiple,"The company must provide satisfactory responses to facility inspection deficiencies, resolve related deficiencies, complete all required Office of Study Integrity and Surveillance inspections, and submit a comprehensive safety update including new safety data, updated exposure information, and worldwide safety experience. All deficiencies listed in the letter must be fully addressed in a resubmission clearly marked 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218923_20250730.pdf
paclitaxel protein-bound particles for injectable suspension (albumin-bound),Accord Healthcare Inc.,"The FDA cannot approve the application in its present form due to deficiencies identified during CGMP inspections of both the drug product facility and the drug substance manufacturing facility. Additionally, the proposed labeling for prescribing information and carton/container labeling is not yet adequate, and a safety update is required.",manufacturing,"The facility must provide satisfactory responses to the deficiencies identified during the CGMP inspections and come into compliance with CGMP. This may require re-inspection. Satisfactory outcomes of both the PAI and CGMP surveillance inspections are needed. The proposed labeling must be made adequate, and a safety update, including new safety data from studies/clinical trials and a summary of worldwide safety experience, must be provided. All deficiencies must be fully addressed in a resubmission.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218762_20241205.pdf
"naloxone HCl nasal spray, 4 mg",Hikma Pharmaceuticals USA Inc.,"The application for naloxone HCl nasal spray, 4 mg, was not approved because the submitted data did not adequately support the proposed nonprescription use, primarily due to safety concerns related to the higher systemic exposure of the proposed product compared to currently approved nonprescription naloxone products. This higher exposure raises concerns about increased risk and severity of precipitated opioid withdrawal, and the current labeling is insufficient to communicate these risks to consumers.",safety,"To gain future approval, the sponsor may consider product reformulation to achieve lower systemic naloxone exposure consistent with approved nonprescription products. Alternatively, to support the currently proposed formulation, the sponsor must establish the safety of the higher systemic exposure for nonprescription use, demonstrating a comparable safety profile to approved nonprescription naloxone products. This may require submitting published literature or data from adequate clinical safety studies, especially in opioid-dependent individuals, to characterize the risk of precipitated withdrawal. Additionally, labeling may need to be modified to ensure adequate comprehension of the product's risks. A safety update with all nonclinical and clinical study data, including any significant changes in the safety profile, reasons for trial discontinuation, case reports for deaths or serious adverse events, updated exposure information, and worldwide safety experience, is also required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA219045_20241021.pdf
irinotecan liposome injection,"Conjupro Biotherapeutics, Inc.","The application cannot be approved in its present form due to significant deficiencies identified during facility inspections, which adversely impact the facility's ability to perform designated functions. Additionally, there are outstanding issues related to clinical inspections (deferred due to travel restrictions), prescribing information, carton and container labeling, proprietary name, and a requirement for a comprehensive safety update including new safety data and re-tabulation of adverse events.",multiple,"The sponsor must address deficiencies identified during facility inspections, provide satisfactory responses to FDA Form 483, and potentially undergo re-inspection. They also need to update the safety data from all nonclinical and clinical studies/trials, including significant changes or findings in the safety profile, retabulation of adverse events, and updated exposure information. Additionally, they must resubmit the proposed proprietary name and address all deficiencies listed in the CRL, clearly marking the submission as 'RESUBMISSION'.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218923_20241010.pdf
glepaglutide injection,"Zealand Pharma US, Inc.","The FDA was unable to conclude that there is substantial evidence of effectiveness (SEE) for glepaglutide injection for the treatment of short bowel syndrome (SBS), nor that the benefits outweigh the known and anticipated risks. Deficiencies were identified in the ability of the submitted data to demonstrate substantial evidence of effectiveness and adequately characterize the safety of the dosage proposed for the treatment of SBS. The data submitted were inadequate to support demonstration of efficacy and safety of glepaglutide for the treatment of adult patients with short bowel syndrome. Specific concerns include the persuasiveness and robustness of the single phase 3 trial (EASE-1) results, issues with missing documentation and data reliability, inadequate qualitative and quantitative analyses, inconsistencies in efficacy results between studies (EASE-1 and EASE-2), and uncertainty regarding the proposed to-be-marketed dosage. Additionally, the safety database was limited, and multiple safety concerns were identified, including potential drug-induced liver injury, cancers, and gastric polyps. An FDA inspection also found unreported adverse events and issues with data reliability.",multiple,"The sponsor is recommended to conduct a second adequate and well-controlled trial before resubmitting the application. This new study should confirm the efficacy of the TBM dosage of glepaglutide and generate additional controlled safety data to support chronic administration, addressing the uncertainties listed in the CRL. The trial should be double-blinded, placebo-controlled, with a treatment period of at least 52 weeks to characterize the safety profile and assess durability of response. Controlled data beyond 24 weeks are necessary to demonstrate maintenance of early PS volume reduction with concurrent maintenance of body weight/nutritional status. Clinically meaningful within-patient score change thresholds for PS volume should be established using anchor-based methods and supplemented with empirical cumulative distribution function curves. Additional data, such as from exit interviews and proportion of patients achieving full enteral autonomy, may be needed. The sponsor must also address deficiencies from a CGMP inspection of a facility and provide a safety update with new and retabulated safety data, including detailed changes, discontinuations, and case reports for serious adverse events and deaths. The proposed proprietary name will be re-evaluated upon resolution of all deficiencies.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA218828_20241219.pdf
govorestat,"Applied Therapeutics, Inc.","The FDA issued a Complete Response Letter for govorestat due to a lack of substantial evidence of effectiveness. The primary clinical trial (Trial AT-007-1002) had major systemic data quality issues related to study conduct, data management, and data replicability, making the efficacy measurements unreliable. Even without these data quality issues, the trial failed to meet its prespecified criteria for statistical significance on primary endpoints. Additionally, the confirmatory evidence regarding govorestat's effect on plasma galactitol and its correlation with clinical outcomes was deemed inadequate, and plasma galactitol was not supported as a reasonably likely surrogate endpoint for accelerated approval.",efficacy,"To gain future approval, the sponsor must provide substantial evidence of effectiveness for govorestat. This requires conducting at least one new adequate and well-controlled trial demonstrating an effect on clinically meaningful endpoint(s) in subjects with classic galactosemia (CG). If relying on a single trial plus confirmatory evidence, a well-designed and adequately powered nonclinical efficacy study in an animal model of CG demonstrating a robust effect of govorestat on clinically relevant neurobehavioral outcomes, histopathology, and metabolic markers of CG should be considered. For accelerated approval, strong mechanistic evidence for galactitol's role as the major mediator in CG pathogenesis, addressing alternative toxic mechanisms, and determining a galactitol reduction threshold predicting clinical benefit are needed. Substantial evidence of effectiveness on a reasonably likely surrogate endpoint (RLSE) based on adequate and well-controlled clinical investigation(s) and confirmatory evidence is also required.",https://github.com/plainyogurt21/CRLs/blob/main/unapproved_CRLs/CRL_NDA219195_20241127.pdf
